Track topics on Twitter Track topics that are important to you
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, cyclophosphamide, melphalan, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy with a peripheral stem cell transplant may allow more chemotherapy to be given so that more cells are killed.
PURPOSE: This phase I/II trial is studying the side effects of giving paclitaxel, cyclophosphamide, melphalan, and etoposide together with peripheral stem cell transplant and to see how well it works in treating patients with stage IIIB inflammatory breast cancer.
- Determine the clinical efficacy of paclitaxel and cyclophosphamide followed by high-dose melphalan and high-dose etoposide with autologous peripheral blood stem cell rescue in patients with stage IIIB inflammatory breast cancer.
- Determine the effect of this regimen on T cells, in terms of number, phenotype, and cytokine profiles, in these patients.
- Determine the process of postchemotherapy T-cell regeneration in patients treated with this regimen.
- Determine the status of a number of key signal transduction pathways that may contribute to the inflammatory breast cancer phenotype.
- Induction chemotherapy: Patients receive induction chemotherapy comprising paclitaxel IV over 24 hours and cyclophosphamide IV over 1 hour on days 1-3. Patients also receive filgrastim (G-CSF) subcutaneously (SC) once or twice daily beginning on day 5 and continuing until apheresis is completed. Treatment repeats every 29 days for up to 3-9 courses. Patients may receive up to 2 additional courses after their best response.
At the discretion of the investigator, patients may also receive up to 4 additional courses of doxorubicin IV and cyclophosphamide IV over 1 hour on day 1 every 21 days to complete induction therapy.
- Apheresis: Peripheral blood stem cells are harvested after the second course (and third course if necessary) of induction chemotherapy to collect adequate CD34+ numbers.
- Transplantation: Beginning at least 21 days after completion of induction chemotherapy, patients receive high-dose melphalan IV over 30 minutes and high-dose etoposide IV over 8 hours on days 1-3. Autologous peripheral blood stem cells are reinfused on day 7. Patients receive G-CSF SC once daily beginning on day 7.
Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 6 months for 2 years.
PROJECTED ACCRUAL: A maximum of 120 patients will be accrued for this study within 3.5 years.
Primary Purpose: Treatment
filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
NCI - Center for Cancer Research
Active, not recruiting
National Cancer Institute (NCI)
Published on BioPortfolio: 2014-08-27T03:56:48-0400
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether combination chemotherapy is more effecti...
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-neg...
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim or filgrastim-SD/01 ma...
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, and paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combinin...
RATIONALE: Drugs used in chemotherapy, such as etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone, use different ways to stop cancer cells from dividing so they stop gro...
We studied rates of granulocyte and platelets recovery in 359 consecutive subjects receiving blood cell infusions in the context of autotransplants for plasma cell myeloma (N = 216) and lymphomas ...
High-dose chemotherapy and autologous stem cell transplantation (ASCT) is the current standard of care for relapsed non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). Conditioning regimens with hig...
The aim of our study was to evaluate the efficacy and toxicity of TECAM (thiotepa, etoposide, cyclophosphamide, cytarabine, and melphalan) and BEAM (carmustine, etoposide, cytarabine, and melphalan) c...
High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party.
A recent shortage of melphalan has prompted the use of alternatives to BEAM (BCNU, Etoposide, Cytarabine, Melphalan) conditioning for autologous stem cell transplantion (ASCT). The BEAC (BCNU, Etoposi...
To compare the pharmacokinetic bioequivalence and safety of a generic pegylated liposomal doxorubicin formulation (SPIL DXR hydrochloride liposome injection) with that of the reference products, Caely...
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
A mixture of six synthetic oligopeptides, each containing MELPHALAN. It is used as a broad-spectrum antineoplastic due to its alkylating and antimetabolic actions but, is toxic to bone marrow, gastrointestinal system and vasculature.
An injectable formulation of albumin-bound paclitaxel NANOPARTICLES.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...